DIAGALS: Relation Between Tar DNA Binding Protein(TDP)-43 et Nrf-2 in ALS: a Track to Improve Diagnosis and Prognosis of the Disease

Regional University Hospital Center (CHRU)

Status

Not yet enrolling

Conditions

Amyotrophic Lateral Sclerosis

Treatments

Biological: Blood sample

Study type

Interventional

Funder types

Other

Identifiers

NCT06230562

DR230136

Details and patient eligibility

About

In response to oxidative stress, cells activate the Nrf-2 pathway, which induces translation of its target genes and corresponding proteins involved in the antioxidant response. This explains the interest in the Nrf-2 pathway in the pathophysiology of Amyotrophic lateral sclerosis (ALS), supported by the results of several studies and the modulatory effect of TDP-43 on the Nrf-2 pathway. Since both TDP-43 and Nrf-2 proteins are present in the peripheral blood mononuclear cells (PBMC) of ALS patients and may be correlated with disease progression, the investigators wish to explore their relationship and their application in the clinic as potential blood biomarkers for ALS.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Patients group :

Inclusion Criteria:

Men and women ≥ 18 years old
Person affiliated to a French social security scheme or equivalent
ALS diagnosed according to El Escorial criteria
Diagnosis of ALS < 6 months
Onset of symptoms < 2 years
Signed informed consent

Non-inclusion criteria :

Pregnant or breast-feeding
Treatment with oral or injectable anticoagulants, antiplatelet agents (EXCEPT aspirin at the maximum authorized dosage of 160 mg per day)
Unbalanced diabetes
Long-term corticosteroid therapy
Persons deprived of their liberty by judicial or administrative decision; Persons under legal protection: guardianship or curators
Genetic mutations associated with ALS

Control group :

Inclusion criteria:

Male or female volunteer aged 18 or over
Person affiliated to a French social security scheme or equivalent
Signed informed consent

Non-inclusion criteria :

Pregnant or breast-feeding women
Treatment with oral or injectable anticoagulants, antiplatelet agents (except aspirin at the maximum authorized dosage of 160 mg per day)
Unbalanced diabetes
Long-term corticosteroid therapy
Neurological diseases
Patient under legal protection (safeguard of justice, curators and guardianship), or in a situation of deprivation of liberty
Genetic mutations associated with ALS